{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-021718","form_type":"8-K","ticker":"BMRN","cik":"0001048477","company_name":"BIOMARIN PHARMACEUTICAL INC","filed_at":"2026-01-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.461974+00:00","generated_at":"2026-05-16T07:48:29.357417+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"BioMarin guides ~$3.2B FY2025 revenue; plans $850M notes + $2.8B loans for Amicus deal","bullets":["FY2025 preliminary total revenue ~$3.2B, including ~$920M from VOXZOGO; cash & investments ~$2.1B.","Launches $850M senior notes due 2034 and $2.8B in term loans ($2B Term Loan B + $800M Term Loan A) plus $600M revolver.","Proceeds escrowed; notes due Dec 2034 subject to special mandatory redemption at 100% if Amicus acquisition fails to close by Dec 19, 2026.","Acquisition of Amicus expected to close in Q2 2026, subject to Amicus stockholder vote and antitrust clearance."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-021718","json":"https://secwatch.observer/filing/0001193125-26-021718.json","markdown":"https://secwatch.observer/filing/0001193125-26-021718.md","text":"https://secwatch.observer/filing/0001193125-26-021718.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1048477/000119312526021718/0001193125-26-021718-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1048477/000119312526021718/d100834d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T07:48:29.357417+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}